Navigation Links
Registry questions superiority of bivalirudin over heparin
Date:5/22/2013

21 May 2013, Paris, France: Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).

European and US NSTE-ACS guidelines currently recommend bivalirudin alone as an alternative to unfractionated heparin plus GP IIb/IIIa receptor inhibitors in patients undergoing an intended urgent or early invasive strategy.

Researchers compared 30-day mortality with heparin alone to that with bivalirudin alone in patients with NSTE-ACS undergoing PCI between 2005 and 2011 in the Swedish coronary angiography and angioplasty registry (SCAAR). The registry records all coronary angiographies and PCIs carried out in Sweden. Results were analysed for 31,351 patients treated with heparin alone and 10,186 given bivalirudin.

Oskar Angers, Consultant Cardiology at Sahlgrenska University Hospital, Gothenburg, Sweden, reported that the adjusted odds ratio for 30-day mortality favoured heparin (1.53 for complete case analysis).

"One should be very careful when interpreting the results, however none of our models show that treatment with bivalirudin improves outcome. The results therefore question the superiority of bivalirudin to heparin in the absence of GP IIb/IIIa blockade in patients with NSTE-ACS undergoing PCI," concluded Angers. "The clinical implication is that if we use heparin alone, we can be assured that it's enough. For those using bivalirudin, switching to heparin achieves similar outcomes and will reduce the cost of procedures." He said that a prospective, randomised trial comparing bivalirudin with heparin in this group of patients is warranted. He added that his group has started the registry-based randomised VALIDATE-SWEDEHEART trial comparing bivalirudin to heparin in patients pretreated with novel ADP-receptor blockers, with the aim of recruiting a total of 6,000 patients.

Commenting on the data, William Wijns, Chairman of PCR and Course Director of EuroPCR, said, "This new data comparing heparin with bivalirudin in NSTE-ACS patients undergoing PCI is very interesting and we await results from new trials looking at this further."


'/>"/>

Contact: Isabelle Uzielli
33-612-233-492
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. New HIV/AIDS registry to help answer key questions
2. PatientCrossroads and Informedika Announce Strategic Partnership to Integrate Lab Results and Rx Data into CONNECT Open Patient Registry
3. Texas Veterinary Cancer Registry Expands Nationally
4. Post-approval TAVI registry shows high rates of device success at 1 year
5. Weirdest hCG Questions Revealed
6. Study questions value of calcium and vitamin D supplements
7. Study Questions Guidelines on Radiation for Older Breast Cancer Patients
8. Researchers awarded National Cancer Institute grants aimed at answering provocative questions
9. Study questions technique to repair ruptured abdominal aortic aneurysms
10. Einstein-Montefiore scientists awarded 2 NCI Provocative Questions grants
11. Study questions the relevance of SCIP benchmarks among CABG patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Tijuana Bariatrics ... which the practice operates, is now dedicated solely to bariatrics. , This means that ... ever before. The expansion of the fourth floor improves the practice’s ability to treat ...
(Date:5/6/2016)... ... ... associated with Mother’s Day is mixed with worry and fear for new mothers those whose ... For the first time ever, the March of Dimes and Random Acts ... beside a crib surrounded by lifesaving equipment or peering through a glass window at a ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... ... 06, 2016 , ... From the Speaker Podium to the Exhibit Floor at ... insights on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 at ... a Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction in ...
(Date:5/6/2016)... ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... he has found in the Bible about helping to stop cancer. Yisrayl says there are ... his hope that the health and science industries will pay close attention and take action. ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 ... the  "Global Actinic Keratosis Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Keratosis epidemiology, Actinic Keratosis market valuations and ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
Breaking Medicine Technology: